NR1D1 and Fulminant hepatitis: REV-ERBα activation is shown to ameliorate ulcerative colitis 25,32,33, fulminant hepatitis 27, neuroinflammation 34,35, heart failure 36,37, myocardial infarction 38, experimental autoimmune encephalomyelitis 33,39, and pulmonary inflammation 29,40.